Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure.
暂无分享,去创建一个
K. Anstrom | E. Braunwald | G. Felker | J. Butler | A. Kalogeropoulos | Adrian F. Hernandez | W. Tang | M. Redfield | M. Konstam | M. Shah
[1] P. Ponikowski,et al. In‐hospital worsening heart failure , 2015, European journal of heart failure.
[2] K. Anstrom,et al. Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF). , 2015, Circulation. Heart failure.
[3] K. Anstrom,et al. Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights from DOSE-AHF and CARRESS-HF , 2015 .
[4] P. Ponikowski,et al. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study‐Heart Failure (ARTS‐HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease , 2015, European journal of heart failure.
[5] Akshay S. Desai,et al. Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial , 2015, Circulation.
[6] K. Anstrom,et al. DECONGESTION STRATEGIES AND RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM ACTIVATION IN ACUTE HEART FAILURE , 2014 .
[7] W. Tang,et al. Utilization pattern of mineralocorticoid receptor antagonists in contemporary patients hospitalized with acute decompensated heart failure: a single-center experience. , 2014, Journal of cardiac failure.
[8] P. Ponikowski,et al. Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial , 2013, European heart journal.
[9] K. Swedberg,et al. Serum aldosterone is associated with mortality and re‐hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial , 2013, European journal of heart failure.
[10] V. Hasselblad,et al. Predictors of early dyspnoea relief in acute heart failure and the association with 30‐day outcomes: findings from ASCEND‐HF , 2013, European journal of heart failure.
[11] B. Massie,et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. , 2013, JACC. Heart failure.
[12] K. Swedberg,et al. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. , 2013, European heart journal.
[13] K. Weber,et al. Mineralocorticoid Receptor Antagonism Confers Cardioprotection in Heart Failure , 2013, Current Heart Failure Reports.
[14] M. Vaduganathan,et al. The disconnect between phase II and phase III trials of drugs for heart failure , 2013, Nature Reviews Cardiology.
[15] R. Schrier,et al. Increased Spironolactone in Advanced Heart Failure: Effect of Doses Greater than 25 mg/Day on Plasma Potassium Concentration , 2013, Cardiorenal Medicine.
[16] Robert O. Bonow,et al. Rehospitalization for heart failure: problems and perspectives. , 2013, Journal of the American College of Cardiology.
[17] K. Anstrom,et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. , 2012, The New England journal of medicine.
[18] P. Kolkhof,et al. Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics , 2012, Molecular and Cellular Endocrinology.
[19] S. Normand,et al. Abstract 13840: National and Regional Trends in Heart Failure Hospitalization and Mortality Rates for Medicare Beneficiaries: 1998-2008 , 2011 .
[20] Mark D. Huffman,et al. Executive Summary: Heart Disease and Stroke Statistics—2015 Update A Report From the American Heart Association , 2011, Circulation.
[21] A. Azevedo,et al. BNP at discharge in acute heart failure patients: is it all about volemia? A study using impedance cardiography to assess fluid and hemodynamic status. , 2010, International journal of cardiology.
[22] P. Ponikowski,et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. , 2010, The New England journal of medicine.
[23] P. Ponikowski,et al. Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes: Lessons Learned and Directions Forward , 2010, Circulation. Heart failure.
[24] D. Mozaffarian,et al. Heart disease and stroke statistics--2010 update: a report from the American Heart Association. , 2010, Circulation.
[25] C. O'connor,et al. Early worsening heart failure in patients admitted with acute heart failure – a new outcome measure associated with long‐term prognosis? , 2009, Fundamental & clinical pharmacology.
[26] S. Normand,et al. Patterns of Hospital Performance in Acute Myocardial Infarction and Heart Failure 30-Day Mortality and Readmission , 2009, Circulation. Cardiovascular quality and outcomes.
[27] R. Schrier,et al. Sodium Retention in Heart Failure and Cirrhosis: Potential Role of Natriuretic Doses of Mineralocorticoid Antagonist? , 2009, Circulation. Heart failure.
[28] D. Mozaffarian,et al. Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2009, Circulation.
[29] D. Mozaffarian,et al. Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2009, Circulation.
[30] R. Califf,et al. Value of Clinician Assessment of Hemodynamics in Advanced Heart Failure: The ESCAPE Trial , 2008, Circulation. Heart failure.
[31] D. Logeart,et al. Transient worsening of renal function during hospitalization for acute heart failure alters outcome. , 2008, International journal of cardiology.
[32] K. Swedberg,et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. , 2007, JAMA.
[33] Karen A. Hartman,et al. Prediction of rehospitalization and death in severe heart failure by physicians and nurses of the ESCAPE trial. , 2007, Journal of cardiac failure.
[34] G. Filippatos,et al. Reassessing treatment of acute heart failure syndromes: the ADHERE Registry , 2005 .
[35] K. Adams,et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). , 2005, American heart journal.
[36] Christopher M O'Connor,et al. Risk stratification after hospitalization for decompensated heart failure. , 2004, Journal of cardiac failure.
[37] A. Ferreira,et al. N-Terminal–Pro-Brain Natriuretic Peptide Predicts Outcome After Hospital Discharge in Heart Failure Patients , 2004, Circulation.
[38] I. Squire,et al. Pre‐discharge, but not admission, levels of NT‐proBNP predict adverse prognosis following acute LVF , 2003, European journal of heart failure.
[39] D. Ellison,et al. Loop diuretic infusion increases thiazide-sensitive Na(+)/Cl(-)-cotransporter abundance: role of aldosterone. , 2001, Journal of the American Society of Nephrology : JASN.
[40] J. Schafer. Multiple imputation: a primer , 1999, Statistical methods in medical research.
[41] L Goldman,et al. Correlates of early hospital readmission or death in patients with congestive heart failure. , 1997, The American journal of cardiology.
[42] A. Donker,et al. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. , 1993, The American journal of cardiology.
[43] J. Ferreira,et al. Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure. , 2014, European journal of internal medicine.
[44] D. Mozaffarian,et al. Executive summary: heart disease and stroke statistics--2010 update: a report from the American Heart Association. , 2010, Circulation.
[45] D. Sica. Pharmacokinetics and Pharmacodynamics of Mineralocorticoid Blocking Agents and their Effects on Potassium Homeostasis , 2005, Heart Failure Reviews.
[46] B. Pitt. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). , 1996, The American journal of cardiology.
[47] W. Abraham,et al. Aldosterone in congestive heart failure: analysis of determinants and role in sodium retention. , 1991, American journal of nephrology.